Resistance of gamma A/gamma ' Fibrin Clots to Fibrinolysis*

(Received for publication, February 19, 1997, and in revised form, April 1, 1997)

Lisa A. Falls and David H. Farrell Dagger

From the Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Elevated plasma fibrinogen levels are a major risk factor for thrombosis. This report shows two mechanisms by which fibrinogen can affect the fibrinolysis rate in vitro and thus may lead to thrombosis. First, the lysis rate of fibrin decreases as the initial concentration of fibrinogen increases. Second, a minor variant form of fibrinogen decreases the rate of fibrinolysis. This variant, gamma A/gamma ' fibrinogen, has one altered gamma  chain and is known to bind to factor XIII zymogen. In a fibrinolysis assay containing purified thrombin, fibrinogen, tissue-type plasminogen activator, and plasminogen, clots from gamma A/gamma A and gamma A/gamma ' fibrinogen lysed at similar rates. However, when factor XIII was added, slower lysis was seen in gamma A/gamma ' fibrin clots when compared with gamma A/gamma A fibrin clots. A D-dimer agglutination assay showed that the gamma A/gamma ' clots were more highly cross-linked than the gamma A/gamma A clots. The lysis rates of gamma A/gamma ' clots were similar to gamma A/gamma A clots in the presence of N-ethylmaleimide, a specific inhibitor of factor XIIIa. The gamma A/gamma ' fibrin clots made in the presence of factor XIII showed increased proteolytic resistance to both plasmin and trypsin. Clots made from afibrinogenemic plasma reconstituted with gamma A/gamma ' fibrinogen also showed significant resistance to lysis compared with gamma A/gamma A fibrinogen. These data demonstrate gamma A/gamma ' fibrin is resistant to fibrinolysis, possibly as a result of concentrating factor XIII on the clot. The total fibrinogen concentration and the amount of gamma A/gamma ' fibrinogen increase clot stability in vitro and thus may contribute independently to the risk of thrombosis in humans.


INTRODUCTION

Fibrinogen is a 340,000-Da dimeric glycoprotein composed of three polypeptide chains, alpha  (Mr = 65,000), beta  (Mr = 56,000), and gamma  (Mr = 47,000) linked by disulfide bonds. Fibrinogen is converted to fibrin through limited proteolysis by thrombin, which exposes polymerization sites in fibrinogen (1). The fibrin monomers spontaneously associate with each other to form the weblike fibrin clot (2). A plasma transglutaminase, factor XIII, strengthens the fibrin clot by forming covalent bonds between adjacent fibrin monomers (3).

Plasma factor XIII is a 320,000-Da tetrameric protein composed of two polypeptide a chains (Mr = 83,000) and two polypeptide b chains (Mr = 80,000) (4). Factor XIII normally circulates as an inactive proenzyme until it is activated by thrombin cleavage of a 4000-Da activation peptide from each a subunit, which is followed by the dissociation of the b subunits. Activated factor XIII, or XIIIa, catalyzes the formation of gamma -glutamyl-epsilon -lysine bonds between polypeptide chains in fibrin (5). These cross-links strengthen the fibrin clot (6) and increase its resistance to lysis (7-9).

Recent evidence has revealed an association between a variant form of fibrinogen and factor XIII that may play a role in modulating the stability of a fibrin clot. This fibrinogen variant, referred to as gamma A/gamma ' fibrinogen, peak II fibrinogen (10), gamma A-gamma B fibrinogen (11), or Fgamma 50, 57.5 (12), contains an altered gamma  chain termed gamma ' (13), gamma B (14), or gamma 57.5 (12), and comprises approximately 7-15% of the total fibrinogen found in plasma (10). The gamma ' chain arises from alternative processing of the gamma  chain mRNA (15, 16) that leads to the translation of a polypeptide with a 20-amino acid sequence substituted for the carboxyl-terminal four amino acids of the gamma  chain. The physiological function of the gamma ' chain remains unclear; however, recent studies have shown that the gamma ' chain binds directly to the zymogen form of factor XIII (17). This suggests that the gamma ' chain of fibrinogen may serve as a carrier for factor XIII to increase the local concentration of factor XIII at the fibrin clot.

Elevated fibrinogen levels are a major risk factor for thrombosis. Several mechanisms have been proposed to explain the correlation between fibrinogen levels and thrombosis (18, 19). Fibrinogen may contribute to thrombosis by its role in atherosclerotic plaque formation. Fibrinogen binds to platelet membranes through glycoprotein IIb-IIIa (integrin alpha IIbbeta 3) and thereby mediates platelet aggregation (20, 21). Fibrin degradation products stimulate the proliferation of vascular smooth muscle cells (22, 23), which may contribute to narrowing of blood vessels during atherosclerosis. In addition, once fibrinogen is incorporated into the atherosclerotic plaque, it binds low density lipoprotein and sequesters more fibrinogen (18), thus enhancing plaque formation. Another mechanism by which fibrinogen may lead to thrombotic disorders is by increasing blood viscosity. Increased blood viscosity favors the hypercoagulable state (24). Furthermore, increased fibrinogen levels lead to increased fibrin deposition (25-27). However, the causal role of these potential factors in thrombosis is still unclear.

The present report demonstrates that increases in total fibrinogen concentration result in increased clot stability toward fibrinolysis in vitro, suggesting a mechanistic explanation of how elevated fibrinogen levels per se may cause an increased risk of thrombosis. In addition, clots made from gamma A/gamma ' fibrinogen are more stable to fibrinolysis in vitro than clots made from gamma A/gamma A fibrinogen. Taken together, these findings suggest that both the total amount of fibrinogen and the amount of gamma A/gamma ' fibrinogen in plasma may be independent risk factors for thrombosis.


EXPERIMENTAL PROCEDURES

Purification of gamma A/gamma A and gamma A/gamma ' Fibrinogen

Plasminogen-free human plasma fibrinogen (Calbiochem) was dissolved in 39 mM Tris-PO4, pH 8.6, containing 5 mM epsilon -aminocaproic acid (EACA)1 and 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and dialyzed exhaustively into the same buffer at 4 °C. Insoluble residue was removed by centrifugation at 10,000 × g for 30 min at 4 °C. The gamma A/gamma A and gamma A/gamma ' forms of fibrinogen were separated using DEAE-cellulose as described previously (28). Briefly, the fibrinogen solution was adsorbed to a column of DEAE-cellulose (6 × 20 cm) and eluted with a 1200-ml exponential gradient generated in a 600-ml constant volume mixing chamber from the starting buffer (39 mM Tris-PO4, pH 8.6, 5 mM EACA, 0.2 mM PMSF) to the final buffer (193 mM Tris-PO4, pH 4.6, 5 mM EACA, 0.2 mM PMSF). The absorbance was monitored at 280 nm, and 11-ml fractions were collected. The elution profile showed two peaks; gamma A/gamma A fibrinogen composed the first peak and gamma A/gamma ' fibrinogen composed the second smaller peak (data not shown).

In some experiments, gamma A/gamma A and gamma A/gamma ' fibrinogen were further purified using a glycine-L-proline-L-arginine-L-proline-L-cysteine (GPRPC)-agarose affinity resin (29). Briefly, the resin was prepared by reacting 10 mg of glycine-L-proline-L-arginine-L-proline-L-cysteine peptide (Howard Hughes Medical Institute Biopolymer Laboratory, Seattle, WA) with 10 ml of 5-thio-2-nitrobenzoate-agarose (Pierce) according to the manufacturer's protocol. The dialyzed gamma A/gamma A or gamma A/gamma ' fibrinogen pool from DEAE-cellulose was adsorbed to a column (3 ml) of GPRPC-agarose, washed with 100 mM NaCl, 50 mM Tris-PO4, pH 7.8, 5 mM EACA, 0.2 mM PMSF, and then washed with 2 M NaBr, 50 mM Tris-PO4, pH 7.8, 5 mM EACA, 0.2 mM PMSF. The fibrinogen was eluted in 1-ml fractions with 2 M NaBr, 20 mM citrate, pH 5.3, 5 mM EACA, 0.2 mM PMSF and immediately neutralized with 0.02 volume of 2 M Tris-HCl, pH 8.0. The fibrinogen fractions were dialyzed into 137 mM NaCl, 2.7 mM KCl, 10 mM HEPES, pH 7.4, 1 mM CaCl2 and stored at -70 °C.

Fibrinolysis Assay Using Purified Components

Microtiter plate fibrinolysis assays were carried out as described previously by Jones and Meunier (30) using 96-well assay plates (Corning 25-880-96). Fibrinogen and Lys-plasminogen (Calbiochem) were added to an interim mixing plate containing assay buffer (0.1 M NaCl, 30 mM NaHCO3, 4 mM KCl, 1 mM CaCl2, 1 mM Na2HPO4, 0.3 mM MgCl2, 0.4 mM MgSO4, 10 mM HEPES, pH 7.4, 0.01% Polysorbate 80). A separate assay plate contained alpha -thrombin (a generous gift from Dr. Walter J. Kisiel, University of New Mexico) and tissue plasminogen activator (Calbiochem) in assay buffer. The fibrinogen/plasminogen solution was then dispensed from the interim plate into the assay plate wells containing thrombin and tissue plasminogen activator. The final concentrations of reagents were 1.25 mg/ml fibrinogen (unless stated otherwise), 30 µg/ml Lys-plasminogen, 16 ng/ml tissue plasminogen activator, and 13.2 NIH units/ml thrombin in a total volume of 100 µl. For assays containing factor XIII (a generous gift from Drs. Michael W. Mosesson and David A. Meh, University of Wisconsin Medical School, Milwaukee Clinical Campus), factor XIII was added to a final concentration of either 10 or 100 µg/ml to the wells in the interim plate containing the plasminogen/fibrinogen mixture. In some assays 1 mM N-ethylmaleimide was also added to the interim plate. The turbidity of the clot was measured at room temperature every 6 min at 405 nm. The optical density was converted to percent lysis as follows,
% <UP>lysis</UP>=<FR><NU>A<SUB>405</SUB>×100%</NU><DE>A<SUB>405</SUB> <UP>maximum</UP></DE></FR> (Eq. 1)
and plotted versus time; the data were then fit to a sigmoidal curve-fitting routine. For clarity, a maximum of 15 data points per set are shown in each graph.

D-Dimer Assay

A D-dimer agglutination assay kit (Sigma) was used to measure D-dimer content in lysed fibrin clots. Clots were formed from gamma A/gamma A or gamma A/gamma ' fibrinogen using 1.0 mg/ml fibrinogen, 13.2 NIH units/ml alpha -thrombin, 16 ng/ml tissue-type plasminogen activator, 30 µg/ml Lys-plasminogen, and 10 µg/ml factor XIII and allowed to lyse completely. After lysis, 50 µl of the lysed clots were serially diluted in the manufacturer's proprietary buffered saline solution, pH 7.3, containing 0.02% sodium azide. 20 µl of the diluted sample were then mixed with 20 µl of a suspension of latex beads coated with mouse monoclonal antibody (MA-8D3) specific for the fibrin D-dimer on the test card. The test card was rocked back and forth, and agglutination was scored after 3 min on duplicate samples.

Trypsin Digest of Fibrin Clots

gamma A/gamma A or gamma A/gamma ' fibrinogen and factor XIII were added to a 96-well assay plate containing assay buffer (0.1 M NaCl, 30 mM NaHCO3, 4 mM KCl, 1 mM CaCl2, 1 mM Na2HPO4, 0.3 mM MgCl2, 0.4 mM MgSO4, 10 mM HEPES, pH 7.4, 0.01% Polysorbate 80), and alpha -thrombin was added to the wells to initiate clotting. The final concentrations of the reagents were 1.0 mg/ml fibrinogen, 10 µg/ml factor XIII, and 13.2 NIH units/ml alpha -thrombin in a total volume of 100 µl. The clots were incubated at room temperature until maximum turbidity was reached. When clotting was complete, 50 µl of 11.7 µg/ml trypsin were added to the clots. The turbidity of the clots was measured every 5 min at 405 nm. The optical density was converted to percent lysis as described above.

Whole Plasma Fibrinolysis Assay

The gamma A/gamma A and gamma A/gamma ' forms of fibrinogen were iodinated with Na125I (DuPont NEN) according to the method of Fraker and Speck (31) to a specific activity of 85,000-120,000 cpm/ng as described previously (29). The plasma fibrinolysis assays were carried out using the method of Wun and Capuano (32). Briefly, the iodinated gamma A/gamma A or gamma A/gamma ' fibrinogen in 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 10 mM HEPES, pH 7.4, was added 1:1 (v/v) to fibrinogen-deficient human plasma (George King Biomedical) at a final concentration of 1.25 mg/ml on ice. (The plasma contained less than 0.1 mg/ml residual fibrinogen.) Clotting of the samples was initiated with 1 NIH unit/ml alpha -thrombin and the clots were incubated at 37 °C in the presence of 0.02% NaN3. Samples were taken daily for 7 days and centrifuged for 5 min in a microcentrifuge to pellet the insoluble clot. 20-µl aliquots of the supernatant were counted in a gamma counter to measure the soluble 125I-fibrin degradation products. The percentage of clot lysis was calculated using the following equation and plotted versus time.
% <UP>lysis</UP>=<FR><NU>(<UP>supernatant cpm</UP>)−(<UP>supernatant cpm @ time zero</UP>)</NU><DE>(<UP>total cpm added</UP>)−(<UP>supernatant cpm @ time zero</UP>)</DE></FR>×100% (Eq. 2)


RESULTS

Fibrinolysis Rates Vary Inversely with Fibrinogen Concentration

Since high plasma fibrinogen levels predispose individuals to a greater risk of thrombosis, we hypothesized that clots made from high concentrations of fibrinogen may be more resistant to fibrinolysis. To test this hypothesis, fibrinolysis assays were performed using purified components, including fibrinogen, thrombin, tissue-type plasminogen activator, and plasminogen (30). Concentrations of fibrinogen from 1 to 4 mg/ml were used, and clotting was initiated by the addition of thrombin. The calculated lysis t1/2 for clots formed from 1, 2, 3, and 4 mg/ml total fibrinogen concentrations was 18.7 ± 0.1, 30.4 ± 0.7, 55.7 ± 0.6, and 70.3 ± 0.3 min, respectively (Fig. 1). The fibrinolysis half-times were essentially linear with respect to the initial fibrinogen concentrations (Fig. 1, inset). Similar results were seen in the absence of factor XIII (data not shown). These results are consistent with other published data (30) and demonstrate that fibrin clots made at high fibrinogen concentrations are more resistant to lysis, suggesting a mechanistic explanation for the role of fibrinogen as a risk factor for thrombosis (33).


Fig. 1. Fibrinolysis rates decrease with increasing fibrinogen concentrations. Fibrinolysis assays using 13.2 NIH units/ml alpha -thrombin, 16 ng/ml tissue-type plasminogen activator, 30 µg/ml Lys-plasminogen, and 10 µg/ml factor XIII were carried out at room temperature using the following concentrations of fibrinogen: 1 mg/ml (bullet ), 2 mg/ml (open circle ), 3 mg/ml (×), and 4 mg/ml (black-square). Clot turbidity was monitored by absorbance at 405 nm and expressed as percent lysis. Each point is the average of duplicate determinations. Inset, the clot lysis t1/2 was determined from each curve and graphed versus fibrinogen concentration.
[View Larger Version of this Image (22K GIF file)]

gamma A/gamma ' Fibrin Clots are Resistant to Fibrinolysis

A second potential risk factor for thrombosis is the amount of gamma A/gamma ' fibrinogen in plasma. This form of fibrinogen has been shown to act as a carrier protein for factor XIII by binding directly to factor XIII via the gamma ' chain (17). We hypothesized that this binding may serve to concentrate factor XIII locally at the surface of the growing fibrin clot, thereby resulting in a more highly cross-linked and stabilized clot. Fibrinolysis assays were therefore carried out using purified gamma A/gamma A or gamma A/gamma ' fibrinogen. As seen in Fig. 2, both the rate of clotting and the rate of lysis were significantly decreased in gamma A/gamma ' fibrin clots. Clots made from gamma A/gamma ' fibrinogen in the presence of factor XIII clotted more slowly and subsequently lysed more slowly (Fig. 2, inset). Clots formed from gamma A/gamma A fibrinogen in the presence of physiological factor XIII concentrations (10 µg/ml) showed a lysis t1/2 of 72 ± 0 min, whereas the clots formed from gamma A/gamma ' fibrinogen had a t1/2 of 179 ± 4 min. Clot stability was enhanced further in the presence of supraphysiological concentrations of factor XIII. In experiments where the factor XIII concentration was increased to 100 µg/ml, the gamma A/gamma A fibrinogen clots showed a lysis t1/2 of 99 ± 1 min, while the clots formed from gamma A/gamma ' fibrinogen had a t1/2 of 207 ± 8 min. These data suggest that factor XIII increases the clotting time as well as decreases the fibrinolysis rates of gamma A/gamma ' fibrin. In the absence of added factor XIII, fibrin clots made from gamma A/gamma A and gamma A/gamma ' fibrinogen clotted and lysed at similar rates, with a lysis t1/2 of 50 ± 1 min for gamma A/gamma A fibrinogen and 54 ± 1 min for gamma A/gamma ' fibrinogen (Fig. 3), demonstrating that the resistance of gamma A/gamma ' fibrin to fibrinolysis is dependent on the presence of factor XIII. Furthermore, when factor XIIIa was inhibited as it was formed during clotting by the prior addition of N-ethylmaleimide, the fibrinolysis rates of gamma A/gamma ' fibrin clots were similar to clots made without factor XIII (data not shown). These data show that active factor XIII is required for the decreased fibrinolysis rate of the gamma A/gamma ' fibrin.


Fig. 2. Fibrinolysis rates of gamma A/gamma ' fibrin clots are slower than gamma A/gamma A fibrin clots. Fibrinolysis assays using 1.25 mg/ml purified fibrinogen, 13.2 NIH units/ml alpha -thrombin, 16 ng/ml tissue-type plasminogen activator, 30 µg/ml Lys-plasminogen, and factor XIII were carried out using gamma A/gamma A fibrinogen with 10 µg/ml factor XIII (bullet ), gamma A/gamma A fibrinogen with 100 µg/ml factor XIII (black-square), gamma A/gamma ' fibrinogen with 10 µg/ml factor XIII (open circle ), and gamma A/gamma ' fibrinogen with 100 µg/ml factor XIII (square ). Clot turbidity was monitored by absorbance at 405 nm and expressed as percent lysis. Each point is the average of duplicate determinations. Inset, the raw absorbance data at 405 nm, showing both the rate of clotting and rate of fibrinolysis, was graphed versus time.
[View Larger Version of this Image (23K GIF file)]


Fig. 3. Fibrinolysis rates of gamma A/gamma A and gamma A/gamma ' fibrin clots are similar in the absence of factor XIII. Fibrinolysis assays using 1.25 mg/ml purified fibrinogen, 13.2 NIH units/ml alpha -thrombin, 16 ng/ml tissue-type plasminogen activator, and 30 µg/ml Lys-plasminogen were carried out using gamma A/gamma A fibrinogen (bullet ) or gamma A/gamma ' fibrinogen (open circle ) in the absence of factor XIII. Clot turbidity was monitored by absorbance at 405 nm and expressed as percent lysis. Each point is the average of triplicate determinations.
[View Larger Version of this Image (13K GIF file)]

A D-dimer agglutination assay was performed to determine if the gamma A/gamma ' fibrin clots were more highly cross-linked than the gamma A/gamma A fibrin clots. As seen in Table I, the lysed gamma A/gamma ' fibrin clots showed positive agglutination down to a dilution of 1:300, whereas the gamma A/gamma A fibrin clots showed positive agglutination down to a dilution of only 1:128. These data show that the gamma A/gamma ' fibrin clots are more highly cross-linked, possibly because of high local concentrations of factor XIII at the clot surface due to binding to the gamma ' chain.

Table I. D-dimer formation in gamma A/gamma A and gamma A/gamma ' fibrin clots

Fibrinolytic digests of gamma A/gamma A or gamma A/gamma ' fibrin were tested for D-dimer content using an agglutination assay. Fibrinolytic digests of gamma A/gamma A or gamma A/gamma ' fibrin were tested for D-dimer content using an agglutination assay.

Dilution Agglutination
 gamma A/gamma A fibrin  gamma A/gamma ' fibrin

1:16 + +
1:32 + +
1:64 + +
1:128 ± +
1:150  - +
1:200  - +
1:256  - +
1:300  - ±
1:350  -  -

It should be noted that these assays were carried out with gamma A/gamma A and gamma A/gamma ' fibrinogen that had been separated on DEAE-cellulose and further purified by GPRPC-agarose chromatography. Factor XIII co-purifies with gamma A/gamma ' fibrinogen on DEAE-cellulose (17), presumably by binding directly to the gamma ' chain in gamma A/gamma ' fibrinogen. We have verified that factor XIII co-purifies with gamma A/gamma ' fibrinogen on DEAE-cellulose, but is depleted from gamma A/gamma ' fibrinogen purified further on GPRPC-agarose (Fig. 4). In experiments using fibrinogen purified only on DEAE-cellulose, the gamma A/gamma ' fibrin clots were resistant to lysis in the absence of added factor XIII (Fig. 5), presumably due to the contaminating factor XIII.


Fig. 4. DEAE-cellulose-purified gamma A/gamma ' fibrinogen contains factor XIII. Two µg/lane gamma A/gamma A or gamma A/gamma ' fibrinogen purified on DEAE-cellulose or DEAE-cellulose/GPRPC-agarose was reduced and separated on a 10% polyacrylamide gel. The proteins were transferred to nitrocellulose, the blot was probed with a goat anti-human factor XIII antibody (1:1000) and stained with a rabbit anti-goat IgG/horseradish peroxidase conjugate using diaminobenzidine. Lane 1, GPRPC-agarose gamma A/gamma '; lane 2, DEAE-cellulose gamma A/gamma '; lane 3, GPRPC-agarose gamma A/gamma A; and lane 4, DEAE-cellulose gamma A/gamma A.
[View Larger Version of this Image (21K GIF file)]


Fig. 5. DEAE-cellulose-purified gamma A/gamma ' fibrinogen is resistant to fibrinolysis without added factor XIII. Fibrinolysis assays using 1.25 mg/ml DEAE-cellulose-purified fibrinogen and 13.2 NIH units/ml alpha -thrombin, 16 ng/ml tissue-type plasminogen activator, and 30 µg/ml Lys-plasminogen were carried out using gamma A/gamma A fibrinogen (bullet ) or gamma A/gamma ' fibrinogen (open circle ). The fibrinogens were purified only on DEAE-cellulose without the use of GPRPC-agarose to remove endogenous factor XIII. Clot turbidity was monitored by absorbance at 405 nm and expressed as percent lysis. Each point is the average of triplicate determinations.
[View Larger Version of this Image (13K GIF file)]

To ensure that the increased lysis resistance was not due to factor XIII affecting the fibrinolytic system directly, gamma A/gamma A and gamma A/gamma ' fibrin clots were formed with thrombin and then digested with trypsin. The gamma A/gamma A fibrin clots had a lysis t1/2 of 5.7 ± 0.2 min, while the gamma A/gamma ' clots had a t1/2 of 39.1 ± 1.8 min (Fig. 6). These data suggest that the increased fibrinolytic resistance of the gamma A/gamma ' fibrin clots is due primarily to proteolytic resistance, although inhibition of the fibrinolytic system cannot be ruled out entirely.


Fig. 6. Cross-linked gamma A/gamma ' fibrin is resistant to trypsin proteolysis. Clot lysis assays using 1 mg/ml purified fibrinogen, 13.2 NIH units/ml alpha -thrombin, 10 µg/ml factor XIII, and 3.9 µg/ml trypsin were carried out at room temperature using gamma A/gamma A fibrinogen (bullet ) or gamma A/gamma ' fibrinogen (open circle ). Clot turbidity was monitored by absorbance at 405 nm and expressed as percent lysis. Each point is the average of duplicate determinations.
[View Larger Version of this Image (13K GIF file)]

gamma A/gamma ' Fibrin Clots in Whole Plasma Are Resistant to Fibrinolysis

Fibrinolysis assays were also carried out in whole plasma (32) to ensure that the effect of gamma A/gamma ' fibrinogen on clot lysis was not an artifact of the purified fibrinolysis assay. gamma A/gamma A and gamma A/gamma ' fibrinogens were iodinated and added to fibrinogen-deficient plasma obtained from an afibrinogenemic individual. Clotting was initiated by adding thrombin, and samples were assayed daily for 7 days to quantitate the amount of soluble fibrin degradation products (Fig. 7). After 7 days, the clots formed from gamma A/gamma A fibrinogen showed complete lysis, with a lysis half-time of 4.3 ± 0.1 days, whereas clots formed from gamma A/gamma ' fibrinogen exhibited no detectable lysis. These results demonstrate that gamma A/gamma ' fibrin clots generated in whole plasma, in which a number of potentially confounding factors are present (particularly protease inhibitors), are also resistant to fibrinolysis.


Fig. 7. gamma A/gamma ' fibrin is resistant to fibrinolysis in whole plasma. gamma A/gamma A (bullet ) and gamma A/gamma ' (open circle ) fibrinogen were iodinated with Na125I and added to fibrinogen-deficient (<0.1 mg/ml) human plasma at 1.25 mg/ml. 50 µl samples were clotted using 1 NIH unit/ml alpha -thrombin and incubated at 37 °C. Samples were taken daily for 7 days and centrifuged 5 min to pellet the clots. Aliquots of the fibrin degradation products in the supernatant were counted with a gamma counter. The percent lysis was calculated as described under "Experimental Procedures."
[View Larger Version of this Image (12K GIF file)]


DISCUSSION

Fibrinolytic therapy is a widely used tool in the treatment of thrombosis. Fibrinolytic agents such as streptokinase or tissue-type plasminogen activator are used to activate the fibrinolytic system by converting the protease zymogen plasminogen to active plasmin, which then cleaves the fibrin clot into soluble components. Unfortunately, the administration of these agents often produces secondary hemorrhagic events that may be life-threatening. The development of new fibrinolytic agents with greater clot specificity is an area of intense study, but less attention has been focused on the factors that determine clot stability. If clot stability could be reduced, then lower amounts of these fibrinolytic agents could be used, thus reducing the chance of adverse side effects.

Increased fibrinogen levels are a major risk factor for cardiovascular disease (18, 19). There are many potential mechanisms to explain how high fibrinogen levels may contribute to the disease process. One possible role is that high fibrinogen levels produce a hypercoagulable state that favors thrombosis. It is known that the plasma levels of fibrinogen have a direct influence on the amount of fibrin formed in clots (25-27). The present study suggests two additional mechanisms through which high fibrinogen levels may lead to thrombosis. In agreement with previously published data, the results show that fibrinolysis rates in vitro vary inversely with fibrinogen concentration (33). This suggests that in hyperfibrinogenemia, there may not only be a greater propensity for a hypercoagulable state, but the clots that result will also be more resistant to lysis. In addition, the present study shows that gamma A/gamma ' fibrinogen affects the stability of fibrin clots formed in vitro, possibly by increasing the local concentration of factor XIII at the clot. Fibrinolysis assays using purified components revealed that clots formed with gamma A/gamma ' fibrinogen show significantly decreased fibrinolysis compared with gamma A/gamma A fibrinogen, but only in the presence of active factor XIII. gamma A/gamma ' fibrin clots are also more highly cross-linked than the gamma A/gamma A fibrin clots, as assessed with a D-dimer agglutination assay. The resistance of gamma A/gamma ' fibrin clots to fibrinolysis was verified in reconstituted whole plasma. These results suggest that gamma A/gamma ' fibrinogen levels in plasma may modulate clot stability by affecting fibrinolysis rates.

The physiological function of gamma A/gamma ' fibrinogen has been elusive for many years. It is clear that the gamma ' chain displays much less binding to the platelet fibrinogen receptor, glycoprotein IIb-IIIa (integrin alpha IIbbeta 3) (11, 29, 34), but this negative role does not explain the raison d'être for gamma A/gamma ' fibrinogen. The present studies suggest that the physiological role of gamma A/gamma ' fibrinogen may be to increase clot stability by localizing factor XIII at the fibrin clot (Fig. 8). In this scenario, unactivated factor XIII is delivered to the growing fibrin clot by gamma A/gamma ' fibrinogen. Through the action of thrombin, fibrinogen (including gamma A/gamma ' fibrinogen) is converted to fibrin. Factor XIII that is bound to the newly formed gamma A/gamma ' fibrin is subsequently activated to XIIIa, since fibrin acts as a positive modulator in factor XIII activation by thrombin (3). Thrombin cleavage dissociates the active a2 dimer from the b subunits of factor XIII, thereby allowing the free a2 dimer to catalyze the cross-linking of the fibrin clot. It is not clear at the present time whether the b subunits remain bound to the gamma ' chain or dissociate with the a2 subunits after thrombin activation. Thus, the delivery of factor XIII to the fibrin clot by gamma A/gamma ' fibrinogen could serve to increase the local concentration of factor XIIIa and result in a more highly stabilized clot.


Fig. 8. A model of factor XIII delivery by gamma A/gamma ' fibrinogen during clotting. Unactivated factor XIII is delivered to the growing fibrin clot carried by gamma A/gamma ' fibrinogen. After thrombin generation, gamma A/gamma ' fibrinogen is converted to fibrin, and factor XIII is activated to XIIIa. Thrombin cleavage dissociates the active a2 dimer from the b subunits of factor XIII, allowing the free a2 dimer to catalyze the cross-linking of the fibrin clot. The delivery of factor XIII to the fibrin clot by gamma A/gamma ' fibrinogen serves to increase the local concentration of factor XIIIa and results in a more highly stabilized clot. It is not clear at the present time whether the b subunits remain bound to the gamma ' chain or dissociate upon thrombin activation of the a2 dimer.
[View Larger Version of this Image (47K GIF file)]

The concentration of gamma A/gamma ' fibrinogen in plasma may therefore be a risk factor for thrombosis, independent of the total plasma fibrinogen concentration. The molecular mechanisms that affect the ratio of gamma A versus gamma ' mRNA transcription are unknown, although the liver expresses both mRNAs, while other tissues express only the gamma A mRNA (35). It is clear that the two mRNAs arise by alternative processing of the original transcript (15, 16); it is possible that the relative amounts of the mRNA pools or their relative translation rates in liver vary among individuals, giving rise to different amounts of gamma A/gamma A and gamma A/gamma ' fibrinogen. There are presently no data available regarding the variability of gamma A/gamma ' fibrinogen levels in human populations. Epidemiologic studies to address this issue are therefore currently underway.


FOOTNOTES

*   This work was supported in part by an American Heart Association, Pennsylvania Affiliate student award (to L. A. F), by Grant H4903 from the W. W. Smith Charitable Trust (to D. H. F.), and an American Heart Association, Pennsylvania Affiliate grant-in-aid (to D. H. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, P. O. Box 850, Hershey, PA 17033-0850. Tel.: 717-531-4098; Fax: 717-531-7072; E-mail: dfarrell{at}bcmic.hmc.psu.edu.
1   The abbreviations used are: EACA, epsilon -aminocaproic acid; GPRPC, glycine-L-proline-L-arginine-L-proline-L-cysteine; PMSF, phenylmethylsulfonyl fluoride.

ACKNOWLEDGEMENTS

We wish to thank Dr. Michael W. Mosesson and Dr. Kevin R. Siebenlist for many helpful discussions, Dr. David A. Meh for factor XIII, and Dr. Walter J. Kisiel for alpha -thrombin.


REFERENCES

  1. Kudryk, B. J., Collen, D., Woods, K. R., and Blombäck, B. (1974) J. Biol. Chem. 249, 3322-3325 [Abstract/Free Full Text]
  2. Blombäck, B. (1996) Thromb. Res. 83, 1-75 [CrossRef][Medline] [Order article via Infotrieve]
  3. Lorand, L., Jeong, J. M., Radek, J. T., and Wilson, J. (1993) Methods Enzymol. 222, 22-35 [Medline] [Order article via Infotrieve]
  4. Schwartz, M. L., Pizzo, S. V., Hill, R. L., and McKee, P. A. (1973) J. Biol. Chem. 248, 1395-1407 [Abstract/Free Full Text]
  5. Chen, R., and Doolittle, R. F. (1969) Proc. Natl. Acad. Sci U. S. A. 63, 420-427 [Abstract]
  6. Lorand, L. (1972) Ann. N. Y. Acad. Sci. 202, 6-30 [Medline] [Order article via Infotrieve]
  7. Gaffney, P. J., and Whitaker, A. N. (1979) Thromb. Res. 14, 85-94 [CrossRef][Medline] [Order article via Infotrieve]
  8. Reed, G. L., Matsueda, G. R., and Haber, E. (1992) Thromb. Haemostasis 68, 315-320 [Medline] [Order article via Infotrieve]
  9. Siebenlist, K. R., and Mosesson, M. W. (1994) J. Biol. Chem. 269, 28414-28419 [Abstract/Free Full Text]
  10. Mosesson, M. W., Finlayson, J. S., and Umfleet, R. A. (1972) J. Biol. Chem. 247, 5223-5227 [Abstract/Free Full Text]
  11. Lawrence, S. O., Wright, T. W., Francis, C. W., Fay, P. J., and Haidaris, P. J. (1993) Blood 82, 2406-2413 [Abstract]
  12. Peerschke, E. I. B., Francis, C. W., and Marder, V. J. (1986) Blood 67, 385-390 [Abstract]
  13. Wolfenstein-Todel, C., and Mosesson, M. W. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 5069-5073 [Abstract]
  14. Francis, C. W., Marder, V. J., and Martin, S. E. (1980) J. Biol. Chem. 255, 5599-5604 [Abstract/Free Full Text]
  15. Chung, D., and Davie, E. W. (1984) Biochemistry 23, 4232-4236 [Medline] [Order article via Infotrieve]
  16. Fornace, A. J., Cummings, D. E., Comeau, C. M., Kant, J. A., and Crabtree, G. R. (1984) J. Biol. Chem. 259, 12826-12830 [Abstract/Free Full Text]
  17. Siebenlist, K. R., Meh, D. A., and Mosesson, M. W. (1996) Biochemistry 35, 10448-10453 [CrossRef][Medline] [Order article via Infotrieve]
  18. Cook, N. S., and Ubben, D. (1990) Trends Pharmacol. Sci. 11, 444-452 [CrossRef][Medline] [Order article via Infotrieve]
  19. Ernst, E. (1995) Ann. Med. 26, 15-22
  20. Bennett, J. S., and Vilaire, G. (1979) J. Clin. Invest. 64, 1393-1401 [Medline] [Order article via Infotrieve]
  21. Marguerie, G. A., Plow, E. F., and Edgington, T. S. (1979) J. Biol. Chem. 254, 5357-5363 [Medline] [Order article via Infotrieve]
  22. Thompson, W. D., and Smith, E. B. (1989) J. Pathol. 159, 97-106 [Medline] [Order article via Infotrieve]
  23. van Pelt-Verkuil, E., van de Ree, P., and Emeis, J. J. (1989) Thromb. Haemostasis 61, 246-249 [Medline] [Order article via Infotrieve]
  24. Yarnell, J. W., Baker, I. A., Sweetnam, P. M., Bainton, D., O'Brien, J. R., Whitehead, P. J., and Elwood, P. C. (1991) Circulation 83, 836-844 [Abstract]
  25. Gurewich, V., Lipinski, B., and Hyde, E. (1976) Thromb. Haemostasis 36, 605-614 [Medline] [Order article via Infotrieve]
  26. Chooi, C. C., and Gallus, A. (1989) Thromb. Res. 53, 493-504 [CrossRef][Medline] [Order article via Infotrieve]
  27. Naski, M. C., and Shafer, J. A. (1991) J. Biol. Chem. 266, 13003-13010 [Abstract/Free Full Text]
  28. Finlayson, J. S., Suchinsky, R. T., and Dayton, A. L. (1960) J. Clin. Invest. 39, 1837-1840
  29. Farrell, D. H., and Thiagarajan, P. (1994) J. Biol. Chem. 269, 226-231 [Abstract/Free Full Text]
  30. Jones, A. J. S., and Meunier, A. M. (1990) Thromb. Haemostasis 64, 455-463 [Medline] [Order article via Infotrieve]
  31. Fraker, P. J., and Speck, J. C., Jr. (1978) Biochem. Biophys. Res. Commun. 80, 849-857 [Medline] [Order article via Infotrieve]
  32. Wun, T.-C., and Capuano, A. (1985) J. Biol. Chem. 260, 5061-5066 [Abstract]
  33. Lewis, M. L., Nachtwey, D. S., and Damron, K. L. (1991) Thromb. Res. 64, 223-234 [Medline] [Order article via Infotrieve]
  34. Farrell, D. H., Thiagarajan, P., Chung, D. W., and Davie, E. W. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10729-10732 [Abstract]
  35. Haidaris, P. J., and Courtney, M. A. (1992) Blood 79, 1218-1224 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.